Products
Online Inquiry
Exisulind
Cat. No.:
0225LY-1351
Appearance:
Solid
Purity:
≥98%
Identity:
Confirmed by NMR, and LC-MS.
Size:
Add to basket
Product Overview
Description:
Exisulind triggers apoptosis by activating protein kinase G (PKG) and demonstrates potent antineoplastic effects across various solid tumors and hematological malignancies, effectively suppressing tumor growth in lung, mammary, bladder, prostate, and colon cancer models.
Synonym:
Sulindac sulfone; CP248; 59973-80-7; Aptosyn; Prevatec; FGN-1; FGN 1; (Z)-Sulindac sulfone; cis-5-Fluoro-2-methyl-1-(p-methylsulfonylbenzylidenyl)indene-3-acetic acid; 5-Fluoro-2-methyl-1-((Z)-p-(methylsulfonyl)benzylidene)indene-3-acetic acid; 1H-Indene-3-acetic acid, 5-fluoro-2-methyl-1-((4-(methylsulfonyl)phenyl)methylene)-, (1Z)-; 2-[(3Z)-6-fluoro-2-methyl-3-[(4-methylsulfonylphenyl)methylidene]inden-1-yl]acetic acid; {(1Z)-5-fluoro-2-methyl-1-[4-(methylsulfonyl)benzylidene]-1H-inden-3-yl}acetic acid; 1H-Indene-3-acetic acid,5-fluoro-2-methyl-1-[[4-(methylsulfonyl)phenyl]methylene]-, (1Z)-; 5-Fluoro-2-methy l-1-((4-(methylsulfonyl)phenyl)methylene)-1H-indene-3-acetic acid
CAS No.:
59973-80-7
Compound CID:
5472495
Formula:
C20H17FO4S
Formula Weight:
372.41
Specification
Relative Density:
1.31 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
Exisulind can be used in cancer prevention studies to investigate the induction of apoptosis via the cGMP phosphodiesterase pathway.
Library Information
Target:
PKA
Receptor:
PKA; PKG
Pathways:
Apoptosis; Tyrosine kinase/adaptors
Plate Number:
AOCL-18
Plate Location:
c9
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10mM DMSO
DMSO Max Solubility:
55 mg/mL; 147.69 mM
